BACKGROUND: Recently we have demonstrated a dose-dependent improvement of endothelial function after administration of a single loading dose of clopidogrel in patients with coronary artery disease (CAD). We therefore hypothesized that chronic therapy with clopidogrel may improve endothelial function in patients with CAD. METHODS: In a double-blind, randomized, monocentric study 120 patients with established CAD were randomized to one of the following treatment arms: clopidogrel 75 mg q.d., acetylsalicylic acid (ASA) 100 mg q.d., or a combination of ASA and clopidogrel. Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-mediated dilation (NMD) of the brachial artery were determined before and after 28 days of treatment. The effect of clopidogrel was monitored in vitro by ADP-induced platelet aggregation in platelet-rich plasma. Effects of treatment on platelet superoxide production were measured by lucigenin-enhanced chemiluminescence in washed platelets. C-reactive protein, RANTES and monocyte chemoattractant protein-1 were determined as inflammatory markers. The study was registered as ISRCTN34097747. RESULTS: Treatment groups were comparable regarding age, gender, cardiovascular risk factor distribution and concomitant medication. FMD [median (IQR) ASA, +0.8 (-2.0; 2.7); ASA + clopidogrel, ±0 (-2.0; 2.9); clopidogrel, +1.0 (-1.1; 2.4); P = n.s.], NMD, platelet superoxide production or inflammatory markers remained unchanged in all treatment groups. CONCLUSION: We conclude that the beneficial effects of short-term effects of clopidogrel on endothelial function of patients with CAD are abolished after long-term clopidogrel treatment.
RCT Entities:
BACKGROUND: Recently we have demonstrated a dose-dependent improvement of endothelial function after administration of a single loading dose of clopidogrel in patients with coronary artery disease (CAD). We therefore hypothesized that chronic therapy with clopidogrel may improve endothelial function in patients with CAD. METHODS: In a double-blind, randomized, monocentric study 120 patients with established CAD were randomized to one of the following treatment arms: clopidogrel 75 mg q.d., acetylsalicylic acid (ASA) 100 mg q.d., or a combination of ASA and clopidogrel. Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-mediated dilation (NMD) of the brachial artery were determined before and after 28 days of treatment. The effect of clopidogrel was monitored in vitro by ADP-induced platelet aggregation in platelet-rich plasma. Effects of treatment on platelet superoxide production were measured by lucigenin-enhanced chemiluminescence in washed platelets. C-reactive protein, RANTES and monocyte chemoattractant protein-1 were determined as inflammatory markers. The study was registered as ISRCTN34097747. RESULTS: Treatment groups were comparable regarding age, gender, cardiovascular risk factor distribution and concomitant medication. FMD [median (IQR) ASA, +0.8 (-2.0; 2.7); ASA + clopidogrel, ±0 (-2.0; 2.9); clopidogrel, +1.0 (-1.1; 2.4); P = n.s.], NMD, platelet superoxide production or inflammatory markers remained unchanged in all treatment groups. CONCLUSION: We conclude that the beneficial effects of short-term effects of clopidogrel on endothelial function of patients with CAD are abolished after long-term clopidogrel treatment.
Authors: Gouri Shanker; Jimmy L Kontos; Delrae M Eckman; Deborah Wesley-Farrington; David C Sane Journal: J Thromb Thrombolysis Date: 2006-12 Impact factor: 2.300
Authors: Lana J Dixon; Sinead M Hughes; Keith Rooney; Aine Madden; Adrian Devine; William Leahey; Welby Henry; G Dennis Johnston; Gary E McVeigh Journal: Am J Hypertens Date: 2005-06 Impact factor: 2.689
Authors: T Waehre; J K Damås; T M Pedersen; L Gullestad; A Yndestad; A K Andreassen; S S Frøland; A G Semb; V Hansteen; E Gjertsen; T Ueland; F Brosstad; N O Solum; P Aukrust Journal: J Thromb Haemost Date: 2006-07-17 Impact factor: 5.824
Authors: A Jakubowski; S Chlopicki; R Olszanecki; J Jawien; M Lomnicka; J P Dupin; R J Gryglewski Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2005-02 Impact factor: 4.006
Authors: Boris Schnorbus; Robert Schiewe; Mir Abolfazl Ostad; Christoph Medler; Daniel Wachtlin; Philip Wenzel; Andreas Daiber; Thomas Münzel; Ascan Warnholtz Journal: Clin Res Cardiol Date: 2009-12-02 Impact factor: 5.460
Authors: Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer Journal: Clin Res Cardiol Date: 2012-01-11 Impact factor: 5.460
Authors: Monica Lisi; Matthias Oelze; Saverio Dragoni; Andrew Liuni; Sebastian Steven; Mary-Clare Luca; Dirk Stalleicken; Thomas Münzel; Franco Laghi-Pasini; Andreas Daiber; John D Parker; Tommaso Gori Journal: Clin Res Cardiol Date: 2012-06 Impact factor: 5.460
Authors: Andrew Haynes; Matthew D Linden; Elisa Robey; Louise H Naylor; Kay L Cox; Nicola T Lautenschlager; Daniel J Green Journal: Physiol Rep Date: 2017-05
Authors: Shabnam Salimi; Joshua P Lewis; Laura M Yerges-Armstrong; Braxton D Mitchell; Faisal Saeed; Jeffry R O'Connell; James A Perry; Kathleen A Ryan; Alan R Shuldiner; Afshin Parsa Journal: J Am Heart Assoc Date: 2016-10-31 Impact factor: 5.501